SEC Comment Letter 0000000000-23-006625 to eFFECTOR Therapeutics, Inc. (EFTR, EFTRW) (CIK 0001828522)
eFFECTOR Therapeutics, Inc. (EFTR, EFTRW) (CIK 0001828522)
Date: June 21, 2023 · CIK: 0001828522 · Accession: 0000000000-23-006625
AI Filing Summary & Sentiment
File numbers found in text: 333-272738
Letter
United States securities and exchange commission logo June 21, 2023 Stephen Worland, Ph.D. Chief Executive Officer eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, California 92075 Re:eFFECTOR Therapeutics, Inc. Registration Statement on Form S-3 Filed June 16, 2023 File No. 333-272738 Dear Stephen Worland: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.
Show Raw Text
United States securities and exchange commission logo
June 21, 2023
Stephen Worland, Ph.D.
Chief Executive Officer
eFFECTOR Therapeutics, Inc.
142 North Cedros Avenue, Suite B
Solana Beach, California 92075
Re:eFFECTOR Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 16, 2023
File No. 333-272738
Dear Stephen Worland:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew T. Bush, Esq.